CEROW
CERo Therapeutics Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
−26.92%Aug 31, 2026, 21:01 UTC
CERO Therapeutics Holdings, Inc. signed a consolidated senior secured promissory note with SRX Global Inc. for up to $11,666,108.77, consolidating previous notes and providing additional advances, with interest at 10% per annum and maturity on October 15, 2026.
Aug 28, 2026, 21:13 UTC
SRX Global Inc. issued 3,579 shares of Series C Convertible Preferred Stock to an accredited investor for $2,862,500, paid via assignment of Convertible Grid Promissory Notes from CERO Therapeutics Holdings, Inc., in a private placement under Regulation D Rule 506(b).
Jul 17, 2026, 00:00 UTC
Cero Therapeutics Holdings, Inc. entered into a Second Amended and Restated Convertible Grid Promissory Note due 2027, providing for maximum aggregate borrowings of $2,085,200, fully funded as of the signing date, with interest at 10% per annum and conversion into common stock.
Jul 10, 2026, 16:00 UTC
Nasdaq Stock Market announced the delisting of common stock and warrants of CERo Therapeutics Holdings, Inc.
Source:Jun 26, 2026, 00:00 UTC
CERO THERAPEUTICS HOLDINGS, INC. amended a convertible promissory note with SRX Health Solutions, Inc., increasing the maximum aggregate principal to $1,413,600 and receiving $663,600 in additional funding.
May 29, 2026, 00:00 UTC
Cero Therapeutics Holdings, Inc. issued a $750,000 convertible promissory note to SRX Health Solutions, Inc., due May 28, 2027, bearing 10% annual interest and convertible into common stock.